ACB

 

ADAP AS OF 7/18/2024 FILL THE SHORT STUDY

 

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	BROKER	DATE AND TIME	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
307	ADAP		RH	7/18/2024	$1.84	10	$18.40	100	$1.20	$120.00	$138.40	110	$1.26	0

Business Summary
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. 

It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. 

The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ACXP

 

ACST 80% DOWN FILL THE SHORT 1:1000 AS OF 7/18/2024

 

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	BROKER	DATE AND TIME	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
271	ACST		RH	7/18/2024	$22.01	1	$22.01	1000	$2.95	$2,950.00	$2,972.01	1001	$2.97	0

ACIU AS OF 7/18/2024 FILL THE SHORT RH

 

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	BROKER	DATE AND TIME	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
283	ACIU		RH	7/18/2024	$4.04	4	$16.16	40	$3.63	$145.20	$161.36	44	$3.67	0